Risk assessment of 2024 cattle H5N1 using age-stratified serosurveillance data

Lin-Lei Chen^{1,2,3*}, Xiaojuan Zhang^{1,2*}, Kang Zhang^{4,5}, Brian Pui-Chun Chan^{1,2}, Jacqueline Kwan Yuk Yuen⁶, Kwok-Yung Yuen^{1,2,3,7,8}, Pui Wang^{1,2,4}, Yuhe R. Yang^{4,9}, Honglin Chen^{1,2,3}, Kelvin Kai-Wang To^{1,2,3,7,8#}

Author affiliations

¹State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China

²Pandemic Research Alliance Unit, University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China

³Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China

⁴CAS Key Laboratory of Nanosystem and Hierarchical Fabrication, National Center for Nanoscience and Technology of China, Beijing 100190, People's Republic of China.

⁵Beijing University of Chemical Technology 100080, People's Republic of China.

Pokfulam, Hong Kong Special Administrative Region, People's Republic of China

⁶Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong,

⁷Department of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region,

People's Republic of China

⁸Department of Infectious Disease and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, People's Republic of China.

⁹ University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China

* These authors contribute equally.

Corresponding authors:

Kelvin Kai-Wang To

Email: kelvinto@hku.hk

Phone number: (852)-22552413

Carol Yu Centre for Infection, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China

Word count: Abstract: 238; Main text: 2480

ABSTRACT

The highly pathogenic avian influenza virus A(H5N1) clade 2.3.4.4b has caused a human outbreak in North America since March 2024. Here, we conducted a serosurveillance study to determine the risk of A(H5N1) clade 2.3.4.4b (2024 cattle H5N1) to general population. In the initial screening of 180 serum specimens encompassing all age groups, 2.2% (4/180) had detectable neutralizing antibody (nAb) titers against 2024 cattle H5N1, with all collected from older adults aged ≥ 60 years old. Further screening showed that 5.0% (15/300) of adults aged ≥ 70 years old had detectable nAb titers against the 2024 cattle H5N1. All serum specimens with nAb titer of \geq 40 had detectable HI titer, and there was a positive correlation between nAb titer and HA binding (r=0.3311, 95% confidence interval 0.2264 to 0.4283; P<0.0001). The nAb titer against seasonal H1N1 virus was 3.9-fold higher for patients with detectable H5N1 nAb than those without (geometric mean titer: 108.5 [95% CI 56.3-209.1] vs 27.9 [95% CI 21.0-37.0], P=0.0039), but there was no statistically significant difference between H5N1 and H3N2 nAb titer. There was no difference in demographics, comorbidities and clinical frailty scores between individuals with detectable H5N1 nAb and those without. Our findings suggest that most individuals lack nAb response against 2024 cattle H5N1 and there is an urgency to develop and evaluate H5N1 vaccine or prophylactic monoclonal antibodies. Immune imprinting may be responsible for the cross neutralization between H5N1 and H1N1 among older adults.

Keywords: Avian influenza virus H5N1 clade 2.3.4.4b, Serosurveillance, Immune imprinting, Elderly, Cattle

INTRODUCTION

The high pathogenic avian influenza (HPAI) virus A(H5N1) was first documented to cause human infections in Hong Kong in 1997 [1]. Subsequent human infections were primarily confined to Western Pacific Region and Egypt [2,3]. However, the subclade 2.3.4.4b, which has caused widespread infections among aquatic and terrestrial wild mammals, pets, farmed minks and dairy cattle [4], caused an unprecedented human outbreak in North America since March 2024. As of 20th December 2024, 65 human cases have been reported, including 64 in the United States and 1 in Canada [5,6]. Most cases in this North American outbreak had exposure to infected dairy cows or poultries [7-9]. Two severe cases have been reported. In November, an adolescent was admitted to critical care for severe H5N1 [5]. On 18th December 2024, the US Centers for Disease Control and Prevention reported a severe case at Louisiana [10].

Several lines of evidence suggest that the clade 2.3.4.4b currently circulating among humans, cattle and other mammals in North America has the potential to become more adapted to humans with pandemic threat. First, unlike earlier H5N1 human infections which were associated with a mortality rate approaching 60%, many recent cattle H5N1 human infections have presented with mild respiratory symptoms and conjunctivitis [7,8]. Investigations among workers at affected dairy farms suggested that 7% to 14.3% had serological evidence of recent H5N1 infection [11,12]. Given the relatively mild clinical presentation, many cases of human H5N1 infections would be unnoticed, facilitating continual transmission in humans for further adaptation and increasing the risk for a pandemic. Second, an H5N1 strain isolated from a patient in the current 2024 United States outbreak was found to replicate efficiently in primary alveolar epithelial cells and can be transmitted between ferrets via respiratory droplets, direct contact or fomite [13]. Third, some key mutations can have a major impact on transmission and human adaptation. An H5N1 strain with PB2-627K (huTx-H5N1) transmitted more efficiently between

ferrets than prior cattle strains without this mutation [13]. A single mutation at haemagglutinin (HA) (G226L) can completely switch the receptor binding specificity from avian type to human type receptor [14]. The recent two severe human cases belong to a new genotype D1.1. The H5N1 from the Canadian case has an HA A144T mutation which can enhance α 2-6 receptor binding [15]. Finally, the H5N1 has been found in a pig in Oregon [16]. Since pigs are well known mixing vessels for different influenza viruses, the ability of H5N1 to infect pig increases the risk of reassortant of H5N1 with seasonal influenza viruses H1N1 or H3N2.

As part of the pandemic preparedness for H5N1, it is essential to estimate the level of population immunity. Neutralizing antibodies (nAbs) are critical in providing protection against influenza viruses [17-19]. In this study, we evaluated the levels of H5N1 nAb in the general population in Hong Kong Special Administrative Region (HKSAR). Our findings indicate that while the majority of individuals lack nAbs against H5N1, a substantial proportion of older adults possess these nAbs, which may be attributable to immune imprinting during childhood.

METHODS

Patient specimens

The first part of this study included 440 random anonymized archived serum samples collected between April and July 2024 from the clinical biochemistry laboratory of Queen Mary Hospital in Hong Kong [19]. For the determination of host factors associated with detectable nAb against 2024 cattle H5N1, we randomly selected 100 serum specimens collected between May and October 2024 from individuals who have been enrolled in our ongoing serological study in older adults, in which we also collected data on demographics, comorbidities, vaccine history and clinical frailty score [20]. The clinical frailty score was determined using the Clinical

Frailty Scale version 2.0 [21]. This study was approved by the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB) (IRB reference numbers UW 22-328 and UW 18-141)

Viruses

All H5N1 influenza viruses used in this study were rescued using the reverse genetics as we described previously with modifications [22]. The eight gene segments of A/dairy cow/Texas/24-008749-003/2024 (2024 cattle H5N1) (GISAID number: EPI_ISL_19014386) or A/Vietnam/1194/04 (2004 human H5N1) (GISAID number: EPI_ISL_30632) were cloned into a pHW2000 plasmid system and used as the backbones. The H1N1 strain (EPI_ISL_19591854) used in the live virus neutralization test was isolated from a nasopharyngeal swab specimen collected in April 2024 and belonged to clade 5a.2a subclade C.1.9, while the H3N2 strain (EPI_ISL_19591855) was isolated from a nasopharyngeal swab specimen collected in January 2024 and belong to clade 2a.3a.1 subclade J.2. All viruses were cultured in Madin-Darby canine kidney (MDCK) cell line (ATCC, Cat# CCL-34). All experiments involving live H5N1 virus were performed in our biosafety level 3 facility.

Live virus neutralization test

Serum specimens were heat inactivated at 56 °C for 30 min and were serially diluted in 2folds starting from 1:10. Duplicates of each serum dilution were mixed with 100 TCID₅₀ of H5N1, H1N1 or H3N2 virus isolates for 1 hour, and the serum-virus mixture was then added to MDCK cells. After incubation for 1.5 h, the mixture was removed, and fresh minimum essential medium (MEM) (Gibco, Catalog no. 11095080) or MEM containing $2\mu g/ml$ L-1-tosylamido-2phenylethyl chloromethyl ketone (TPCK)-treated trypsin (Sigma, Catalog no. T1426) was added to each well. After incubation for 3 days, cytopathic effect (CPE) was examined. The nAb titer was defined as the highest dilution with 50% inhibition of CPE. For the purpose of statistical analysis, a value of 5 was assigned if CPE was observed at a dilution of 1:10. A value of 2560 was assigned if CPE was not observed at a dilution of 1:2560.

Generation of 2024 cattle H5N1 trimer

The expression plasmid vector for 2024 cattle H5N1 was sourced from the Addgene plasmid repository (pCD5-H3TX12-CO-GCN4-TEV-sfGFP-TS #158739). The expression plasmid was constructed by inserting the vector GCN4-TEV-sfGFP-TwinStrep (C terminal on insert). For protein expression, pCD5-H5N1–GCN4-TEV-sfGFP-TwinStrep plasmid was transfected into HEK293F cells. Culture supernatant was harvested 4 days post-transfection. HA was purified using Strep-Tactin resin columns and nickel affinity columns. To remove TEV protease and sfGFP fluorescent protein, further purification was performed using SuperdexTM 200 Increase 10/300 size-exclusion chromatography (SEC) column. The HA expression was verified with sodium dodecyl sulfate–polyacrylamide gel electrophoresis.

Enzyme immunoassay (EIA) for 2024 cattle H5 hemagglutinin

The EIA for the 2024 cattle H5 HA protein was performed as we described previously with modifications [23]. Briefly, 96-well half area polystyrene high binding microplates (Corning, Catalog no. 3690) were coated with $50 \square \mu$ L of 2024 cattle H5N1 HA protein ($50 \square$ ng/well) in 0.05 \square M NaHCO₃ (pH 9.6) overnight at $4 \square$ °C. After blocking with blocking reagent overnight at $4 \square$ °C, $50 \square \mu$ L of heat-inactivated human serum samples at 1:100 dilution or a mouse anti-H5N1 monoclonal antibody were added to the wells and incubated at $37 \square$ °C for $1 \square$ h. Human or mouse immunoglobulin G (IgG) were detected using horseradish-peroxidase (HRP)-conjugated goat anti-human IgG (Thermo Fisher Scientific, Catalog no. 31430), respectively. The

reaction was developed by adding diluted 3,3',5,5'-tetramethylbenzidine single solution (TMB) (Invitrogen, Catalog no. 002023) and stopped with $0.3 \square N H_2SO_4$. The optical density (OD) was read at 450 and 620 \square nm.

Haemagglutinin inhibition (HI) assay

HI assay was performed as we described previously [24]. Briefly, non-specific inhibitors in sera were removed by incubation with receptor destroying enzyme (RDE) and preadsorption with turkey erythrocyte. Serial 2-fold dilutions of serum from 1:10 were titrated against 4 HA units of A/dairy cow/Texas/24-008749-003/2024 using 0.5% turkey erythrocyte.

Statistical analysis

Statistical analysis was performed using GraphPad Prism version 10.4.0 or SPSS version 26. Mann Whitney U test and Fisher's exact test were used for continuous and categorical variables, respectively. The correlation between log-transformed nAb titer and HA EIA OD values was computed using Pearson correlation. Log-transformed nAb titer was used statistical analysis. A P value of <0.05 was considered statistically significant.

RESULTS

We first screened for nAb against H5N1 viruses among 180 archived anonymized serum specimens collected in June to July 2024, including 20 specimens for each 10-year age cohort from 0-9 to \geq 80-year-old cohorts. The serum nAb titers against the 2024 cattle H5N1 were determined using live virus neutralization test. Overall, 2.2% (4/180) of serum specimens had detectable nAb against 2024 cattle H5N1 (Table 1). Subgroup analysis showed that the proportion of individuals with detectable nAb against 2024 cattle H5N1 was highest for the \geq 80-year-old age cohort (10% [2/20]), followed by 70-79-year-old cohort (5% [1/20]), and the 60-69

year-old cohorts (5% [1/20]. None of the individuals in age cohorts of 50-59 year-old or younger had detectable nAb against the cattle H5N1. Only 1 of 180 (0.6%) serum specimens had detectable nAb against the clade 1 2004 human H5N1 strain. We further tested the nAb titers of an additional 260 anonymized archived serum specimens collected from individuals \geq 70 years old between April and July 2024. Out of a total of 300 anonymized serum specimens collected from older adults aged \geq 70 years, 5.0% (15/300) had detectable 2024 cattle H5N1 nAb, with 1.3% (4/300) having an nAb titer of \geq 40 (Table 2). 12 serum specimens had detectable nAb against 2024 cattle H5N1 but not 2004 human H5N1, 2 had detectable 2004 human H5N1 but not 2024 cattle H5N1, and 3 sera had detectable nAb against 2024 cattle H5N1 and 2004 human H5N1.

Next, we determined whether H5N1 nAb targets the HA. The proportion of individuals with detectable HI titer is significantly higher for sera with 2024 cattle nAb \geq 10 than those without detectable nAb titer (60% vs 9.8%, P<0.001) (Table 3). Notably, all 4 serum specimens with nAb titer of \geq 40 had detectable HI titer. The 2024 cattle H5N1 nAb titer also positively correlated with the HA binding in the EIA (r=0.3311, 95% confidence interval 0.2264 to 0.4283; P<0.0001) (Figure 1).

Since both H5 and H1 belong to HA phylogenetic group 1 [25], we hypothesize that the observed H5N1 serum neutralizing activity was related to cross reactivity from H1N1 nAb. To address this hypothesis, we determined the nAb titer against a 2024 H1N1 strain and a 2024 H3N2 strain for all 25 serum specimens collected from older adults aged \geq 70 years who had detectable cattle H5N1 nAb titer. We also analyzed 75 randomly selected serum specimens from the same age cohort without detectable cattle H5N1 nAb titer. The H1N1 nAb titer was 3.9-fold higher for patients with detectable H5N1 nAb titer than those without detectable H5N1 nAb titer

(geometric mean titer [GMT]: 108.5 [95% CI 56.3-209.1] vs 27.9 [95% CI 21.0-37.0], P=0.0039 [Mann Whitney U test]), but there was no statistically significant difference in the H3N2 nAb titer between patients with detectable cattle H5N1 nAb titer than those without (GMT: 30.3 [95% CI 19.6-46.9] vs 18.6 [95% CI 14.9-23.1], P=0.2990 [Mann Whitney U test]) (Figure 2).

To determine if there were any host factors that were associated with detectable 2024 cattle H5N1 nAb, we retrieved 100 serum specimens collected from older adults aged \geq 70 years old between May and October 2024 who were enrolled in ongoing serosurveillance study [20]. There were no significant differences between those with detectable cattle H5N1 nAb and those without in terms of age, sex, comorbidities, influenza vaccination history and clinical frailty score (Table 4).

DISCUSSION

Serosurveillance has been an indispensable tool to understand population immunity during the A(H1N1)pdm09 and the COVID-19 pandemic [26,27]. In this study, we utilized serosurveillance to evaluate the risk posed by the 2024 clade 2.3.4.4b cattle H5N1 to the general public. Our initial screening of 180 anonymized serum specimens obtained from various age groups revealed that only 2.2% had detectable nAb titers against the 2024 cattle H5N1. These findings underscore the vulnerability of our population to H5N1. Consequently, if the H5N1 were to become more transmissible among humans, there is a possibility of rapid surge in patients that could potentially overwhelm the healthcare system, similar to the situation for A(H1N1)pdm09 and COVID-19 pandemics.

H1N1, but not H3N2, nAb titer was statistically significantly higher among those with detectable H5N1 nAb. Our results suggest that there are cross reactive nAb in these serum

specimens that neutralize both H1N1 and H5N1. Both HA and neuraminidase (NA) can be the target of broadly reactive nAb. For HA, previous studies demonstrated that the stalk region and the vestigial esterase domain of the HA protein are the targets of broadly reactive Ab that neutralizes both H5N1 and H1N1 [28,29]. For NA, prophylactic treatment with anti-NA monoclonal antibodies, which targets the lateral face of NA, could protect mice against lethal H1N1 or H5N1 infection [30]. Future studies should assess the role of NA nAb in the neutralization of H5N1 viruses.

Age-stratified analysis indicated that all serum specimens with detectable cattle H5N1 nAb were obtained from individuals aged 60 years or above, while none of the 120 individuals aged between 0 and 59 years old had detectable cattle H5N1 nAb. Our results suggest that immune imprinting due to childhood exposure to H1N1 or H2N2 may elicit nAb that cross neutralize H5N1. Our results are consistent with the observations in previous studies. Gostic *et al* demonstrated that childhood imprinting with H1N1 was associated with 75% protection against severe H5N1 infection [31]. Supporting this, a study in ferrets showed that immune imprinting with H1N1 increases the survival rates for H5N1 infection [32]. Similarly, in mice infected with H5N1, those primed with H1 HA had less weight loss when compared to those primed with H3 HA [33].

Another possible reason for having H5N1 nAb is repeated vaccination against influenza virus. Using pseudovirus neutralization test, Wang *et al* showed that 36% of adults aged 48-64 years old who have received multiple seasonal influenza vaccines from 2004 to 2009 had nAb of \geq 160 against the H5N1 Vietnam/1203/04, though none had nAb of \geq 160 against several other H5N1 strains isolated from 2002-2006 [34]. However, in our study, we did not observe any statistically significant difference among individuals who have received influenza vaccine and

those who did not. Therefore, it is unlikely that repeated seasonal influenza vaccination can reliably elicit H5 nAb.

There are several limitations. First, this study was conducted in HKSAR where H5N1 and other subtypes of avian influenza viruses exposure may be more frequent than some areas, especially before the implementation of stringent live poultry market measures [2]. Hence, there is a possibility that some individuals may indeed have prior exposure to H5N1 or H5Nx. Second, caution is warranted when comparing our results from those of others, as different assays were employed. In our current study, we used a conventional live virus neutralization test. However, other studies have used pseudovirus neutralization test or HI assay only [11,12].

Our serosurveillance study showed that our general population is vulnerable to H5N1 infection. Currently, 2 of 65 (3.1%) of cases in the North American clade 2.3.4.4b outbreak require critical care. The clade 2.3.4.4b H5N1 virus can cause fatal infection in ferrets and mice [13,35]. There is an urgent need to develop and evaluate H5N1 vaccine against the clade 2.3.4.4b before this virus becomes pandemic.

ACKNOWLEDGEMENTS

We would like to thank Geriatric Medicine Research of Dalhousie University for their permission to use the Clinical Frailty Scale. This work was supported by the Partnership Programme of Enhancing Laboratory Surveillance and Investigation of Emerging Infectious Diseases and Antimicrobial Resistance for the Department of Health, HKSAR. We acknowledge funding received from private donors, including Richard Yu and Carol Yu, Shaw Foundation Hong Kong, May Tam Mak Mei Yin, Michael Seak-Kan Tong, Respiratory Viral Research Foundation Limited, Lee Wan Keung Charity Foundation Limited, Providence Foundation

Limited (in memory of the late Lui Hac-Minh), Hui Ming, Hui Hoy and Chow Sin Lan Charity

Fund Limited, Chan Yin Chuen Memorial Charitable Foundation, the Chen Wai Wai Vivien

Foundation Limited and Marina Man-Wai Lee.

CONFLICT OF INTEREST

All authors declare no conflict of interest.

REFERNCES

[1] Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-71

[2] To KK, Ng KH, Que TL, Chan JM, Tsang KY, Tsang AK, et al. Avian influenza A H5N1 virus: a continuous threat to humans. Emerg Microbes Infect 2012;1:e25

[3] To KK, Chan JF, Chen H, Li L, Yuen KY. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect Dis 2013;13:809-21

[4] Caserta LC, Frye EA, Butt SL, Laverack M, Nooruzzaman M, Covaleda LM, et al. Spillover of highly pathogenic avian influenza H5N1 virus to dairy cattle. Nature 2024;634:669-76

[5] Dyer O. Bird flu: Canadian teenager is critically ill with new genotype. BMJ 2024;387:q2529

[6] Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. Available at <u>https://www.cdc.gov/bird-flu/situation-summary/index.html</u>. Accessed on 20th December 2024. 2024

[7] Uyeki TM, Milton S, Abdul Hamid C, Reinoso Webb C, Presley SM, Shetty V, et al. Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Dairy Farm Worker. N Engl J Med 2024;390:2028-9

[8] Morse J, Coyle J, Mikesell L, Stoddard B, Eckel S, Weinberg M, et al. Influenza A(H5N1) Virus Infection in Two Dairy Farm Workers in Michigan. N Engl J Med 2024;391:963-4

[9] Centers for Disease Control and Prevention. CDC A(H5N1) Bird Flu Response Update November 18, 2024. Available at <u>https://www.cdc.gov/bird-flu/spotlights/h5n1-response-</u> 11152024.html. Accessed on 22 November 2024. 2024

[10] Centers for Disease Control and Prevention. CDC Confirms First Severe Case of H5N1 Bird Flu in the United States. Available at <u>https://www.cdc.gov/media/releases/2024/m1218-h5n1-flu.html</u>. Accessed on 20th December 2024. 2024

[11] Shittu I, Silva D, Oguzie JU, Marushchak LV, Olinger GG, Lednicky JA, et al. A One Health Investigation into H5N1 Avian Influenza Virus Epizootics on Two Dairy Farms. medRxiv 2024;10.1101/2024.07.27.24310982:2024.07.27.24310982

[12] Mellis AM, Coyle J, Marshall KE, Frutos AM, Singleton J, Drehoff C, et al. Serologic Evidence of Recent Infection with Highly Pathogenic Avian Influenza A(H5) Virus Among Dairy Workers - Michigan and Colorado, June-August 2024. MMWR Morb Mortal Wkly Rep 2024;73:1004-9

[13] Gu C, Maemura T, Guan L, Eisfeld AJ, Biswas A, Kiso M, et al. A human isolate of bovine H5N1 is transmissible and lethal in animal models. Nature 2024;10.1038/s41586-024-08254-7

[14] Lin TH, Zhu X, Wang S, Zhang D, McBride R, Yu W, et al. A single mutation in bovine influenza H5N1 hemagglutinin switches specificity to human receptors. Science 2024;386:1128-34

[15] Dadonaite B, Ahn JJ, Ort JT, Yu J, Furey C, Dosey A, et al. Deep mutational scanning of H5 hemagglutinin to inform influenza virus surveillance. PLoS Biol 2024;22:e3002916

[16] U.S. Department of Agriculture. Federal and State Veterinary Agencies Share Update on HPAI Detections in Oregon Backyard Farm, Including First H5N1 Detections in Swine. Available at <u>https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-</u>

agencies-share-update-hpai-detections-oregon. Accessed on 20th December 2024. 2024 [17] Jia M, Zhao H, Morano NC, Lu H, Lui YM, Du H, et al. Human neutralizing antibodies

[17] Jia W, Zhao H, Worano KC, Ed H, Ed TW, Dd H, et al. Human neutralizing antibodic target a conserved lateral patch on H7N9 hemagglutinin head. Nat Commun 2024;15:4505
 [18] Tsang TK, Cauchemez S, Perera RA, Freeman G, Fang VJ, Ip DK, et al. Association between antibody titers and protection against influenza virus infection within households. J Infect Dis 2014;210:684-92

[19] Chen LL, Wu WL, Chan WM, Fong CHY, Ng ACK, Ip JD, et al. Assessment of population susceptibility to upcoming seasonal influenza epidemic strain using interepidemic emerging influenza virus strains. Epidemiol Infect 2019;147:e279

[20] Zhang X, Lam SJ, Ip JD, Fong CH, Chu AW, Chan WM, et al. Characterizing fitness and immune escape of SARS-CoV-2 EG.5 sublineage using elderly serum and nasal organoid. iScience 2024;27:109706

[21] Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-95

[22] Song W, Wang P, Mok BW, Lau SY, Huang X, Wu WL, et al. The K526R substitution in viral protein PB2 enhances the effects of E627K on influenza virus replication. Nat Commun 2014;5:5509

[23] Cai JP, Chu WM, Tam AR, Wang K, Han Y, Chen LL, et al. Determination of seroprevalence and kinetics of humoral response using mpox virus A29 protein. Commun Med (Lond) 2023;3:168

[24] To KK, Hung IF, Lui YM, Mok FK, Chan AS, Li PT, et al. Ongoing transmission of avian influenza A viruses in Hong Kong despite very comprehensive poultry control measures: A prospective seroepidemiology study. J Infect 2016;72:207-13

[25] Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013;64:189-202

[26] Public Health Collaborators on Serosurveillance for Pandemic P, Response P. Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response. Lancet 2023;402:356-8

[27] Fragaszy EB, Quinlivan M, Breuer J, Craig R, Hutchings S, Kidd M, et al. Populationlevel susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE). Public Health Research;10.3310/phr03060. Southampton (UK)2015.

[28] Zheng Z, Paul SS, Mo X, Yuan YA, Tan YJ. The Vestigial Esterase Domain of Haemagglutinin of H5N1 Avian Influenza A Virus: Antigenicity and Contribution to Viral Pathogenesis. Vaccines (Basel) 2018;6

[29] Guthmiller JJ, Han J, Utset HA, Li L, Lan LY, Henry C, et al. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature 2022;602:314-20

[30] Hansen L, McMahon M, Turner HL, Zhu X, Turner JS, Ozorowski G, et al. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity 2023;56:1927-38 e8

[31] Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 2016;354:722-6

[32] Nunez IA, Jang H, Huang Y, Kelvin A, Ross TM. Influenza virus immune imprinting dictates the clinical outcomes in ferrets challenged with highly pathogenic avian influenza virus H5N1. Front Vet Sci 2023;10:1286758

[33] Carreno JM, Strohmeier S, Kirkpatrick Roubidoux E, Hai R, Palese P, Krammer F. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model. mBio 2020;11

[34] Wang W, Alvarado-Facundo E, Chen Q, Anderson CM, Scott D, Vassell R, et al. Serum Samples From Middle-aged Adults Vaccinated Annually with Seasonal Influenza Vaccines Cross-neutralize Some Potential Pandemic Influenza Viruses. J Infect Dis 2016;213:403-6
[35] Pulit-Penaloza JA, Belser JA, Brock N, Kieran TJ, Sun X, Pappas C, et al. Transmission of a human isolate of clade 2.3.4.4b A(H5N1) virus in ferrets. Nature 2024;10.1038/s41586-024-

08246-7

FIGURE LEGEND

Figure 1. Correlation between neutralizing antibody titer against 2024 cattle H5N1 and binding to 2024 cattle H5 HA. HA binding was determined using EIA with 2024 cattle H5 HA trimer. Each bar represents the mean and standard deviation, and each dot represents the optical density value in the HA EIA. HA, hemagglutinin; nAb, neutralizing antibody; OD, optical density

Figure 2. Comparison of nAb titer against seasonal influenza viruses between patients with detectable nAb against cattle H5 and those without detectable nAb against H5. A) H1N1; B) H3N2. Dotted line indicates the lower detection limit. Horizontal bars represent the geometric mean nAb titer with 95% confidence interval. **, P < 0.01

	No. of individuals with neutralizing antibody titer of ≥ 10 (%)		
	2024 Cattle H5N1	2004 human H5N1	
Anonymized serum specimens collected			
in July 2024			
All age groups (n=180)	4 (2.2)	1 (0.6)	
0-9 year (n=20)	0 (0)	0 (0)	
10-19 year (n=20)	0 (0)	0 (0)	
20-29 year (n=20)	0 (0)	0 (0)	
30-39 year (n=20)	0 (0)	0 (0)	
40-49 year (n=20)	0 (0)	0 (0)	
50-59 year (n=20)	0 (0)	0 (0)	
60-69 year (n=20)	1 (5)	0 (0)	
70-79 year (n=20)	1 (5)	0 (0)	
80 years or above (n=20)	2 (10)	1 (5)	

Table 1. Proportion of individuals with detectable neutralizing antibody against 2024 cattleH5N1 or 2004 human H5N1

Data expressed as no. (%)

Neutralizing antibody titer	No. of individuals (%)		
	(n=300)		
	2024 Cattle H5N1	2004 human H5N1	
≥10	15 (5.0)	5 (1.7)	
≥40	4 (1.3)	0 (0.0)	
≥80	1 (0.3)	0 (0.0)	

Table 2. Proportion of anonymized older adults (≥70 years old) with detectable neutralizing antibody against 2024 cattle H5N1 or 2004 human H5N1

Data expressed as no. (%)

nAb titer	% of sera with HI titer ≥10
<10 (n=285)	28 (9.8)
≥10 (n=15)	9 (60)
10 (n=6)	2 (33.3)
20 (n=5)	3 (60)
40 (n=3)	3 (100)
80 (n=1)	1 (100)

Table 3. Proportion of anonymized older adults (≥70 years old) with HI titers for each nAb titer

Data expressed as no. (%)

	2024 cattle H5N1 nAb titer		P value ^a
	<10	≥10	
	(n=90)	(n=10)	
Demographics			
Median age (range)	73 (70-75)	71 (70-75)	0.106
Female sex	56 (62.2)	9 (90)	0.159
Comorbidities		- (= 0)	
Hypertension	64 (71)	7 (70)	1.000
Heart disease	50 (56)	5 (50)	0.750
Lung disease	9 (10)	1 (10)	1.000
Liver disease	18 (20)	2 (10)	1.000
Kidney disease	7 (7.8)	1 (10)	0.583
Autoimmune disease	1 (1)	1 (10)	0.191
Hematological	13 (14)	2 (20)	0.643
disorders			
Malignancy	13 (14)	1 (10)	1.000
Diabetes mellitus	30 (33)	3 (30)	1.000
Thyroid disease	12 (13)	0 (0)	0.604
Influenza vaccine			
2020-2021 season	51 (57)	6 (60)	1.000
2021-2022 season	46 (51)	4 (40)	0.741
2022-2023 season	55 (61)	6 (60)	1.000
2023-2024 season	71 (79)	7 (70)	0.687
2024-2025 season	15 (17)	1 (10)	1.000
Have not received	14 (15.6)	3 (30)	0.367
influenza vaccine from			
2020 to 2024			
Median clinical frailty	3 (2-5)	3 (2-3)	0.656
score (range)			

Table 4. Host factors associated with detectable 2024 cattle H5N1 nAb

Data expressed as no. (%) unless otherwise stated

Abbreviations: SD, standard deviation

^a Fisher's exact test for categorical variables; Mann Whitney U test for continuous variables



nAb against 2024 cattle H5N1

